## Abstract ## Background Children with cancer frequently develop anemia both from the disease and from chemo‐ and radiotherapy. Considered a manageable complication, anemia is often not treated until it becomes severe, i.e., hemoglobin (Hb) level ≤ 7 g/dL. The most frequent treatment employed for
Introduction: Managing anemia in pediatric cancer patients
✍ Scribed by Voûte, P.A.
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 36 KB
- Volume
- 39
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
✦ Synopsis
Supplement based on the proceedings of a satellite symposium at SIOP 2000 in Amsterdam (''Anemia in Pediatric Cancer Patients-How to Manage It?''), and also on the pediatric session of a stand-alone symposium held in Seville, Spain in 2000 (''Evolving Issues in Oncology: What is the 'Optimal' Hemoglobin Level?'').
📜 SIMILAR VOLUMES
## Abstract ## Background Anemia occurs frequently in children with cancer, but there is little information quantifying the incidence of anemia or treatment. A survey was conducted in 1998 in Europe by The Research Partnership with the objective of determining the incidence of anemia, identifying
## Background: Pulmonary disease in the pediatric cancer patient continues to pose a difficult clinical dilemma. bronchoalveolar lavage (bal) is commonly utilized for the diagnosis of pulmonary complications in the immunocompromised child. ## Procedure: We retrospectively reviewed 53 bal procedur
## Abstract ## BACKGROUND Data on darbepoetin alfa for anemia management in patients with chronic kidney disease (CKD) is scarce when compared with epoetin alfa. Clinical experiences of using darbepoetin alfa, dosing guide, and average weekly requirements are discussed in this article. ## METHODS